TO EVALUATE THE EFFICACY AND SAFETY OF ORMELOXIFEN IN TREATMENT OF MENORRHAGIA

Volume : VII, Issue : VI, June - 2018

Dr Rajkishori Dandotiya, Dr Paribhashita Mishra

OBJECTIVE: 1.To evaluates the efficacy of Ormeloxifene in the medical management of menorrhagia.2. To findout side effects of

Ormeloxifene.

STUDY DESIGN AND SETTING: The descriptive observational study was conducted in Department of Obstetrics and

Gynecology, G.R.Medical College and Kamla Raja Hospital, Gwalior (Madhya Pradesh) from January 2017 to December 2017.

MATERIAL AND METHOD: One hundred women of reproductive age group with menorrhagia were recruited for the study.

These patients were given ormeloxifene 60 mg twice a week for 12 weeks from first day of periods and once a week for next 12

weeks. Parameters assessed were Mean blood loss (MBL) by PBAC score, duration of bleeding, presence of blood clots and mean

rise in hemoglobin after 6 months of treatment and changes in these parameters were analyzed by student‘s paired‘ tests using

SPSS 16.0 version ,p value ≤ 0.05 was taken as significant.

RESULT: The mean pre–treatment MBL (PBAC score) was 450.5 which reduced to 60 at 6 months with ormeloxifene and was

found to be statistically significant (p–value ≤0.001). Mean duration of bleeding pretreatment was 7.4days which was reduced to

2 days after 6 months of treatment with ormeloxifene. This reduction in duration of bleeding was statistically significant

(P<0.001).The mean rise in hemoglobin was 1.4 which was also statistically significant. The decrease in endometrial thickness in

patients on ormeloxifene was 1.13 which was not significant (p–0.09).

CONCLUSION: Ormeloxifene is very effective in treatment of menorrhagia. It decrease duration of bleeding, passage of blood

clots and improve hemoglobin effectively. Ormeloxifene is accepted well and has good patient compliance due to its minimal

adverse effects, low cost and simple dosage schedule.